Several Factors Predict Early Death in Elderly Patients Receiving Chemotherapy

Share this content:

(ChemotherapyAdvisor) – Advanced disease, a low Mini Nutritional Assessment (MNA) score, male sex, and poor mobility predicted early death in patients with cancer >70 years of age, investigators concluded in the Journal of Clinical Oncology online April 16.

Patients >70 years scheduled to receive first-line chemotherapy for colon, pancreas, stomach, ovary, bladder, prostate, lung, non-Hodgkin's lymphoma, or cancer of unknown primary origin (excluding breast cancer), were included in the study, which sought to identify objective factors that predict early death, defined as <6 months after initiation of chemotherapy.

Baseline abbreviated comprehensive geriatric assessment (aCGA), including the Mini-Mental State Exam, Timed Get Up and Go (GUG), Activities of Daily Living (ADL), Instrumental Activities in Daily Living (IADL), MNA, Geriatric Depression Scale (GDS15), and comorbidities index (Cumulative Index Rating Scale-Geriatric), was conducted. Prognostic factors of early death were sought from aCGA results and traditional oncology measures.

Median patient age was 77.45 years; the ratio of men to women was 1.47; and 65% of patients had advanced disease.

Of the 348 patients from 12 centers in Southwest France, abnormal aCGA scores were observed for 18.1% on the ADL, 73.0% on the IADL, 24.1% on the GUG, 19.0% on the MMS, 44.0% on the GDS15, and 64.9% on the MNA. Advanced disease (OR, 3.9), low MNA score (OR, 2.77), male sex (OR, 2.40), and long GUG (OR, 2.55) were associated with higher risk of early death.

“We recommend that the MNA and GUG, performed by a trained nurse, be maintained as part of routine pretreatment workup in these patients to identify at-risk patients and to inform the decision-making process for chemotherapy,” they concluded.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs